211 related articles for article (PubMed ID: 18085322)
1. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine.
Sarton E; Teppema L; Dahan A
Adv Exp Med Biol; 2008; 605():486-91. PubMed ID: 18085322
[TBL] [Abstract][Full Text] [Related]
2. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil.
Freye E; Neruda B; Smith OW
Arzneimittelforschung; 1997 Jan; 47(1):6-9. PubMed ID: 9037435
[TBL] [Abstract][Full Text] [Related]
3. Opioid-induced respiratory effects: new data on buprenorphine.
Dahan A
Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
[TBL] [Abstract][Full Text] [Related]
4. Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis.
Janas A; Folwarczna J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):175-185. PubMed ID: 27896372
[TBL] [Abstract][Full Text] [Related]
5. Tolerance and cross-tolerance to the rate-suppressing effects of opioids in butorphanol-treated rats: influence of maintenance dose and relative efficacy at the mu receptor.
Smith MA; Picker MJ
Psychopharmacology (Berl); 1998 Nov; 140(1):57-68. PubMed ID: 9862403
[TBL] [Abstract][Full Text] [Related]
6. Naloxone reversal of buprenorphine-induced respiratory depression.
Gal TJ
Clin Pharmacol Ther; 1989 Jan; 45(1):66-71. PubMed ID: 2491980
[TBL] [Abstract][Full Text] [Related]
7. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.
La Vincente SF; White JM; Somogyi AA; Bochner F; Chapleo CB
Clin Pharmacol Ther; 2008 Jan; 83(1):144-52. PubMed ID: 17568402
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats.
Chevillard L; Mégarbane B; Risède P; Baud FJ
Toxicol Lett; 2009 Dec; 191(2-3):327-40. PubMed ID: 19819313
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Stinus L; Cador M; Zorrilla EP; Koob GF
Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
[TBL] [Abstract][Full Text] [Related]
10. Naloxone reversal of buprenorphine-induced respiratory depression.
van Dorp E; Yassen A; Sarton E; Romberg R; Olofsen E; Teppema L; Danhof M; Dahan A
Anesthesiology; 2006 Jul; 105(1):51-7. PubMed ID: 16809994
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
Schuh KJ; Walsh SL; Bigelow GE; Preston KL; Stitzer ML
J Pharmacol Exp Ther; 1996 Aug; 278(2):836-46. PubMed ID: 8768738
[TBL] [Abstract][Full Text] [Related]
12. Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: quantitative antagonism by naloxone.
Shannon HE; Cone EJ; Gorodetzky CW
J Pharmacol Exp Ther; 1984 Jun; 229(3):768-74. PubMed ID: 6547177
[TBL] [Abstract][Full Text] [Related]
13. Studies of the pharmacology and pathology of intrathecally administered 4-anilinopiperidine analogues and morphine in the rat and cat.
Yaksh TL; Noueihed RY; Durant PA
Anesthesiology; 1986 Jan; 64(1):54-66. PubMed ID: 2867722
[TBL] [Abstract][Full Text] [Related]
14. Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil.
Amin HM; Sopchak AM; Esposito BF; Henson LG; Batenhorst RL; Fox AW; Camporesi EM
J Pharmacol Exp Ther; 1995 Jul; 274(1):34-9. PubMed ID: 7616418
[TBL] [Abstract][Full Text] [Related]
15. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
[TBL] [Abstract][Full Text] [Related]
17. Blocking of enhanced sensitivity to behavioral effects of naloxone induced by narcotic agonists in rats.
Jain R; Ray R
Indian J Physiol Pharmacol; 2003 Oct; 47(4):407-14. PubMed ID: 15266952
[TBL] [Abstract][Full Text] [Related]
18. Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration.
Canestrelli C; Marie N; Noble F
Int J Neuropsychopharmacol; 2014 Sep; 17(9):1367-73. PubMed ID: 24606726
[TBL] [Abstract][Full Text] [Related]
19. The counteraction of opioid-induced ventilatory depression by the serotonin 1A-agonist 8-OH-DPAT does not antagonize antinociception in rats in situ and in vivo.
Guenther U; Manzke T; Wrigge H; Dutschmann M; Zinserling J; Putensen C; Hoeft A
Anesth Analg; 2009 Apr; 108(4):1169-76. PubMed ID: 19299781
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial.
Zamani N; Buckley NA; Hassanian-Moghaddam H
Crit Care; 2020 Feb; 24(1):44. PubMed ID: 32033582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
